Saga, Japan

Naoshi Hagihara


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Naoshi Hagihara: Innovator in Immunotoxin Therapy

Introduction

Naoshi Hagihara is a prominent inventor based in Saga, Japan. He has made significant contributions to the field of immunotoxin therapy, particularly in the treatment of brain tumors. His innovative approaches aim to enhance the efficacy of immunotoxins while minimizing vascular damage.

Latest Patents

Hagihara holds a patent titled "Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy." This invention addresses the challenge of vascular toxicity that limits the administration of immunotoxins into the brain. By using endosome pH-raising agents, such as lysosomotrophic amines and proton ionophores, the invention increases the therapeutic window of immunotoxins. This advancement enhances the likelihood of effective treatment for brain tumors.

Career Highlights

Naoshi Hagihara is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work focuses on developing strategies to improve the safety and effectiveness of immunotoxin therapies. His research has the potential to significantly impact the treatment landscape for brain tumors.

Collaborations

Hagihara collaborates with Richard J. Youle, a fellow researcher in the field. Their combined expertise contributes to advancing the understanding and application of immunotoxin therapies.

Conclusion

Naoshi Hagihara's innovative work in immunotoxin therapy represents a significant advancement in the treatment of brain tumors. His patent and ongoing research efforts highlight the importance of protecting vascular health during therapy. This work has the potential to improve patient outcomes and expand the therapeutic applications of immunotoxins.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…